Cancer Prevention: Obstacles, Challenges, and the Road Ahead
Authors:
- Frank L. MeyskensFMFrank L. Meyskens
- Hasan MukhtarHMHasan Mukhtar
- Cheryl L. RockCRCheryl L. Rock
- Jack CuzickJCJack Cuzick
- Thomas W. KenslerTKThomas W. Kensler
- Chung S. YangCYChung S. Yang
- Scott D. RamseySRScott D. Ramsey
- Scott M. LippmanSLScott M. Lippman
- David S. AlbertsDADavid S. Alberts
Open Access
- 7 November 2015
- journal article
- review article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 108 (2)
Abstract
Approaches to reduce the global burden of cancer include two major strategies: screening and early detection and active preventive intervention. The latter is the topic of this Commentary and spans a broad range of activities. The genetic heterogeneity and complexity of advanced cancers strongly support the rationale for early interruption of the carcinogenic process and an enhanced focus on prevention as a priority strategy to reduce the burden of cancer; however, the focus of cancer prevention management should be on individuals at high risk and on primary localized disease in which screening and detection should also play a vital role. The timing and dose of (chemo-)preventive intervention also affects response. The intervention may be ineffective if the target population is very high risk or already presenting with preneoplastic lesions with cellular changes that cannot be reversed. The field needs to move beyond general concepts of carcinogenesis to targeted organ site prevention approaches in patients at high risk, as is currently being done for breast and colorectal cancers. Establishing the benefit of new cancer preventive interventions will take years and possibly decades, depending on the outcome being evaluated. We also propose that comparative effectiveness research designs and the value of information obtained from large-scale prevention studies are necessary in order for preventive interventions to become a routine part of cancer management.Keywords
This publication has 102 references indexed in Scilit:
- Cancer chemoprevention: a rapidly evolving fieldBritish Journal of Cancer, 2013
- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer PatientsJNCI: Journal of the National Cancer Institute, 2012
- Was race a factor in the outcomes of the women's health eating and living study?Cancer, 2011
- Cancer Biomarkers: Can We Turn Recent Failures into Success?JNCI: Journal of the National Cancer Institute, 2010
- The Use of Animal Models for Cancer Chemoprevention Drug DevelopmentSeminars in Oncology, 2010
- Case–control study of lifetime total physical activity and endometrial cancer riskCancer Causes & Control, 2010
- Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statementThe Lancet Oncology, 2009
- Multiple Novel Prostate Cancer Predisposition Loci Confirmed by an International Study: The PRACTICAL ConsortiumCancer Epidemiology, Biomarkers & Prevention, 2008
- Physical activity, sedentary behavior, and the risk of colon and rectal cancer in the NIH-AARP Diet and Health StudyCancer Causes & Control, 2008
- Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move ForwardClinical Cancer Research, 2006